Abstract
The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Keywords: T cells, cyclosporine A, prednisolone
Current Signal Transduction Therapy
Title: The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Volume: 4 Issue: 3
Author(s): Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Thomas Rojewski, Baoan Chen, Marlies Gotz, Philippe Guillaume, Donald Bunjes and Michael Schmitt
Affiliation:
Keywords: T cells, cyclosporine A, prednisolone
Abstract: The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Export Options
About this article
Cite this article as:
Fei Fei, Yu Yingzhe, Schmitt Anita, Rojewski Thomas Markus, Chen Baoan, Gotz Marlies, Guillaume Philippe, Bunjes Donald and Schmitt Michael, The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057502
DOI https://dx.doi.org/10.2174/157436209789057502 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design Nutrition in Infancy
Current Pediatric Reviews The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
Current Gene Therapy A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma
Current Cancer Drug Targets Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy